{
  "abstract": "Background and Importance The addition of bevacizumab to trifluridine/tipiracil (Bev-TAS) treatment has shown improved survival compared to monotherapy in metastatic colorectal cancer (mCRC).Aim and Objectives To evaluate the effectiveness and safety of Bev-TAS in clinical practice at a second-level hospital.Material and Methods Observational, retrospective study including patients with mCRC treated with Bev-TAS between 19/01/2023-25/09/2025.Data collected form electronic medical records included: demographic (age, sex), clinical (date of diagnosis, stage, location, mutations, metastases, previous treatments and ECOG), treatment-related (start/end dates, number of cycles), effectiveness [response rate per RECIST V1.1, progression-free survival (PFS) and overall survival (OS)] and safety (adverse reactions (ARs) per NCI-CTCAEv.5, dose reductions and discontinuations). Effectiveness was assessed by Kaplan-Meier method, using SPSS v1.Results Thirty-seven patients were included (27 men); median age was 76 years (IQR 66-75,5). Primary tumour was in colon in 75,7% (left: 18, right: 9, unknown: 1) and 24,3% in rectum. Mutations were found in 59,5% (51,4% KRAS, 5,4% NRAS, 2,7% BRAF V600E). The most frequent metastases sites were liver (n=25), lungs (n=16) and peritoneum (n=6). The median previous treatments received was two (IQR 2-2) and the ECOG was 1 (n=32), 0 (n=3) and 2 (n=2). Median follow-up after treatment initiation was 12 months (IQR 6–22).The median number of Bev-TAS cycles was five (IQR 3-11). Best response was: 13,5% partial response, 46% stable disease, 35,1% progressive disease and 5,4% not evaluable. The disease control rate was 59,5%.Median PFS was 5 months (95% CI 2,4-7,6) and OS was 12 months (95% CI 9,5-14,6).ARs occurred in 89,2% of patients, mostly grade (G) 1-2: Asthenia (n=19), nausea/vomiting (n=9), diarrhoea (n=7), neutropenia (n=6) and thrombopenia (n=4). G3-4 included: Neutropenia (n=9), asthenia (n=4), hypertension (n=1), thrombopenia (n=1).Treatment delays due to ARs occurred in 51,4% (median 7 days (IQR 7–17,5)) and dose reductions in 18,9%. Treatment was discontinued in 70,3%, due to progression (n=21), ARs (n=4) and clinical deterioration (n=1).Conclusion and Relevance Our study showed effectiveness and safety outcomes consistent with those reported in the pivotal SUNLIGHT trial, supporting the benefit of adding bevacizumab to trifluridine/tipiracil in real-world practice. Safety profile and dose reductions were also comparable, with the most frequent ARs being haematological and gastrointestinal disorders.Conflict of Interest No conflict of interest",
  "authors": [
    {
      "affiliations": [
        "Complejo Hospitalario Universitario De Ferrol, Servicio De Farmacia, Ferrol, Spain"
      ],
      "name": "V Lores Tojeiro"
    },
    {
      "affiliations": [
        "Complejo Hospitalario Universitario De Ferrol, Servicio De Farmacia, Ferrol, Spain"
      ],
      "name": "T Gonzalez Furelos"
    },
    {
      "affiliations": [
        "Complejo Hospitalario Universitario De Ferrol, Servicio De Farmacia, Ferrol, Spain"
      ],
      "name": "L Lopez Sandomingo"
    },
    {
      "affiliations": [
        "Complejo Hospitalario Universitario De Ferrol, Servicio De Farmacia, Ferrol, Spain"
      ],
      "name": "M Granero Lopez"
    }
  ],
  "title": "4CPS-261 Bevacizumab and trifluridine-tipiracil for metastasic colorectal cancer: retrospective analysis in a second-level hospital",
  "uid": "01d22a56-9877-56ac-b531-43d269acb61f"
}